Metabolic
Half-life: ~7 days (enabling once-weekly dosing)
Survodutide
Survodutide (BI 456906)
Survodutide represents the cutting edge of obesity pharmacology: a dual agonist that activates both GLP-1 and glucagon receptors. While this might seem counterintuitive—glucagon raises blood sugar—the combination produces synergistic effects for weight loss. GLP-1 activation suppresses appetite, slows gastric emptying, and improves insulin secretion, just like semaglutide. Glucagon receptor activation adds something semaglutide lacks: increased energy expenditure through liver-mediated pathways and enhanced fat burning. The result, in phase 2 trials, was up to 19% weight loss at 46 weeks—competitive with tirzepatide's best results. Developed by Boehringer Ingelheim, survodutide is also being studied for NASH (fatty liver disease) and liver fibrosis, where the glucagon component may offer particular benefits by reducing liver fat. The challenge is balancing potency with tolerability; glucagon can raise blood sugar, potentially limiting use in diabetics. As obesity drug development accelerates, survodutide positions itself as a potentially best-in-class option by attacking the problem from multiple angles.
Table of Contents
What is Survodutide?
Survodutide represents the cutting edge of obesity pharmacology: a dual agonist that activates both GLP-1 and glucagon receptors. While this might seem counterintuitive—glucagon raises blood sugar—the combination produces synergistic effects for weight loss. GLP-1 activation suppresses appetite, slows gastric emptying, and improves insulin secretion, just like semaglutide. Glucagon receptor activation adds something semaglutide lacks: increased energy expenditure through liver-mediated pathways and enhanced fat burning. The result, in phase 2 trials, was up to 19% weight loss at 46 weeks—competitive with tirzepatide's best results. Developed by Boehringer Ingelheim, survodutide is also being studied for NASH (fatty liver disease) and liver fibrosis, where the glucagon component may offer particular benefits by reducing liver fat. The challenge is balancing potency with tolerability; glucagon can raise blood sugar, potentially limiting use in diabetics. As obesity drug development accelerates, survodutide positions itself as a potentially best-in-class option by attacking the problem from multiple angles.
Research Benefits
Substantial weight loss (up to 19% in trials)
Appetite suppression via GLP-1
Increased energy expenditure via glucagon
May improve fatty liver disease
Reduces liver fibrosis markers
Once-weekly dosing
Potential metabolic benefits beyond weight
Additive effects from dual mechanism
Research Applications
Obesity treatment
Active research area with published studies
Non-alcoholic steatohepatitis (NASH)
Active research area with published studies
Liver fibrosis
Active research area with published studies
Metabolic syndrome
Active research area with published studies
Type 2 diabetes (careful dosing)
Active research area with published studies
Cardiovascular risk reduction
Active research area with published studies
Body composition optimization
Active research area with published studies
Fatty liver disease
Active research area with published studies